Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4573 Monotherapy in r/r PTCL and cHL
NCT05140382Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of zemirciclib in peripheral T-cell lymphoma (PTCL), classical Hodgkin lymphoma (cHL), sponsored by AstraZeneca. Started Dec 2021; status: completed.
02
Drugs
zemirciclib
03
Conditions
peripheral T-cell lymphoma (PTCL)classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05140382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140382.